Vanguard Group Inc Tcr2 Therapeutics Inc. Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.0 - $1.62 $37,456 - $60,678	37,456 Added 2.62%	1,468,802 $2.2 Million
Q4 2022 Feb 10, 2023	SELL	$0.83 - $1.44 $1,725 - $2,993	-2,079 Reduced 0.15%	1,431,346 $1.43 Million
Q3 2022 Nov 14, 2022	BUY	$1.86 - $3.75 $184,262 - $371,497	99,066 Added 7.42%	1,433,425 $2.58 Million
Q2 2022 Aug 12, 2022	BUY	$2.11 - $2.94 $640,304 - $892,178	303,462 Added 29.44%	1,334,359 $3.87 Million
Q1 2022 May 13, 2022	SELL	$2.4 - $4.71 $767,712 - $1.51 Million	-319,880 Reduced 23.68%	1,030,897 $2.85 Million
Q4 2021 Feb 14, 2022	SELL	$4.58 - $8.34 $473,091 - $861,480	-103,295 Reduced 7.1%	1,350,777 $6.3 Million
Q3 2021 Nov 12, 2021	BUY	$8.44 - $18.35 $546,169 - $1.19 Million	64,712 Added 4.66%	1,454,072 $12.4 Million
Q2 2021 Aug 13, 2021	BUY	$16.41 - $24.71 $22.8 Million - $34.3 Million	1,389,360 New	1,389,360 $22.8 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.